HELX

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Ken GriffinCitadel Advisors $-1.8M ExitQ3 2025 $1.8M -- --
Ken GriffinCitadel Advisors $-1.8M ExitQ3 2025 $1.8M -- --
Ken GriffinCitadel Advisors $510.8K AddQ2 2025 $511k -- --
Ken GriffinCitadel Advisors $510.8K AddQ2 2025 $511k -- --
Ken GriffinCitadel Advisors $1.0M AddQ1 2025 $1.0M -- --
Ken GriffinCitadel Advisors $1.0M AddQ1 2025 $1.0M -- --

Trade HELX

About Franklin Genomic Advancements ETF

This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emerging economies. The core investment thesis of the fund centers on companies engaged in genomic advancements. Specifically, it seeks out firms that the investment manager believes are fundamentally dedicated to, or are poised to significantly benefit from, efforts to prolong and enhance the overall quality of life for both humans and animals. This is accomplished by integrating cutting-edge technological and scientific innovations, improvements, and breakthroughs in the field of genomics directly into their business models and operations.

IPO Date: Feb 27, 2020

Market Data

Open: $35.06
High: $35.42
Low: $35.06
Volume: 5
52W High: $38.17
52W Low: $26.90

Valuation

Market Cap: $18M

Financials

Financial statement snapshot is not available yet.

Events

DividendDec 30

$0.14334